Other antidiabetics such as dipeptidyl peptisase-4 (DPP-4) and sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) agonists, thiazolidinediones, and sulfonylureas also reduced the risk of mortality in diabetic patients with COVID-19 [219, 220]. This evidence concerns the gene DPP4 and COVID-19.